Haloperidol Syri

Haloperidol Syri is an oral formulation of the generic drug haloperidol, a butyrophenone antipsychotic. While the specific strength is not disclosed, the product is marketed in the European Union and is available by prescription only. Haloperidol works by blocking dopamine D2 receptors, which helps manage symptoms of certain psychiatric conditions. It is classified under ATC code N05AD01 and is typically used under the supervision of a qualified healthcare professional.

Haloperidol Syri is prescribed for several psychiatric indications where dopamine blockade is therapeutic, and it may be used as part of a broader treatment plan.

- Management of schizophrenia, including acute exacerbations. - Treatment of acute psychotic episodes unrelated to schizophrenia. - Control of manic episodes in bipolar disorder. - Reduction of severe agitation or aggression in hospitalized patients. - Adjunctive therapy for Tourette syndrome when other options are insufficient. - Prevention of relapse in patients stabilized on haloperidol therapy. - Use in combination with other antipsychotics when monotherapy is inadequate.

Haloperidol Syri can produce a range of adverse effects, which are generally categorized by frequency and severity; patients should be monitored regularly for both common and potentially serious reactions.

Common: - Extrapyramidal symptoms such as tremor, rigidity, and akathisia. - Drowsiness or sedation. - Dry mouth and constipation. - Weight gain or increased appetite. - Blurred vision or ocular disturbances. - Nausea or vomiting. - Orthostatic hypotension. - Insomnia or sleep disturbances. - Sexual dysfunction, such as decreased libido.

Serious: - Neuroleptic malignant syndrome, a life‑threatening reaction. - Tardive dyskinesia, characterized by involuntary movements. - Significant cardiac arrhythmias, including QT prolongation. - Severe depression or suicidal thoughts. - Hepatic dysfunction with elevated enzymes. - Seizures in predisposed individuals. - Elevated prolactin levels leading to galactorrhea.

When prescribing Haloperidol Syri, clinicians consider several precautionary factors to minimize risk and ensure appropriate use.

- Assess patient history for cardiovascular disease, especially arrhythmias or prolonged QT interval. - Evaluate for movement disorders or prior extrapyramidal reactions before initiating therapy. - Use caution in patients with hepatic or renal impairment; dose adjustments may be required. - Monitor for signs of neuroleptic malignant syndrome during the first weeks of treatment. - Consider pregnancy and lactation status; the safety profile in these populations is not well established. - Review concomitant medications that may increase the risk of sedation or cardiac effects.

Haloperidol Syri may interact with other medicines, altering its effectiveness or increasing adverse effects; awareness of key interactions guides safe prescribing.

Avoid: - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma levels. - Other antipsychotics or dopamine antagonists that may exacerbate extrapyramidal symptoms. - Medications known to prolong the QT interval, such as certain antiarrhythmics or fluoroquinolones.

Use with caution: - CNS depressants (e.g., benzodiazepines, opioids) that can increase sedation. - Anticholinergic agents, which may mask early signs of extrapyramidal side effects. - CYP2D6 substrates (e.g., metoprolol, codeine) where haloperidol may affect their metabolism.